Evidence map›Paper›PMID 41400662›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Duration of antibiotic therapy: how short is short enough?]

Florian Hitzenbichler

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Florian HitzenbichlerAbteilung für Krankenhaushygiene und Infektiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93042, Regensburg, Deutschland. florian.hitzenbichler@ukr.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shortening the duration of antibiotic therapy in various infections is safe and effective, as supported by evidence from randomized controlled trials. This strategy not only reduces antibiotic consumption and clinical side effects, but also shortens the length of hospital stay without affecting mortality and recurrence rates. This review summarizes current evidence from randomized controlled trials on the optimal treatment duration of bacteremia, pneumonia, urinary tract infections and other infections. For bacteremia with established source control, 7 days of antibiotic treatment is sufficient for most pathogens. For community-acquired pneumonia, 5-7 days, and for hospital-acquired pneumonia, 7-8 days are recommended by national guidelines. Certain infections still require longer treatment, with examples including endocarditis, bone and joint infections and tuberculosis.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsBacteremiaCommunity-Acquired InfectionsCross InfectionDrug Administration ScheduleHumansLength of StayRandomized Controlled Trials as TopicUrinary Tract InfectionsAnti-Bacterial AgentsBacteremiaCommunity-acquired pneumoniaEndocarditisHealthcare-associated pneumoniaUrinary tract infections

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.